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Abstract. We describe a cell-molecular based evolutionary mathematical model of tumor de-
velopment driven by a stochastic Moran birth-death process. The cells in the tumor carry molecular
information in the form of a numerical genome which we represent as a four-digit binary string used
to differentiate cells into 16 molecular types. The binary string is able to undergo stochastic point
mutations that are passed to a daughter cell after each birth event. The value of the binary string
determines the cell fitness, with lower fit cells (e.g. 0000) defined as healthy phenotypes, and higher
fit cells (e.g. 1111) defined as malignant phenotypes. At each step of the birth-death process, the
two phenotypic sub-populations compete in a prisoner’s dilemma evolutionary game with the healthy
cells playing the role of cooperators, and the cancer cells playing the role of defectors. Fitness, birth-
death rates of the cell populations, and overall tumor fitness are defined via the prisoner’s dilemma
payoff matrix. Mutation parameters include passenger mutations (mutations conferring no fitness
advantage) and driver mutations (mutations which increase cell fitness). The model is used to ex-
plore key emergent features associated with tumor development, including tumor growth rates as it
relates to intratumor molecular heterogeneity. The tumor growth equation states that the growth
rate is proportional to the logarithm of cellular diversity/heterogeneity. The Shannon entropy from
information theory is used as a quantitative measure of heterogeneity and tumor complexity based
on the distribution of the 4-digit binary sequences produced by the cell population. To track the
development of heterogeneity from an initial population of healthy cells (0000), we use dynamic
phylogenetic trees which show clonal and sub-clonal expansions of cancer cell sub-populations from
an initial malignant cell. We show tumor growth rates are not constant throughout tumor develop-
ment, and are generally much higher in the subclinical range than in later stages of development,
which leads to a Gompertzian growth curve. We explain the early exponential growth of the tumor
and the later saturation associated with the Gompertzian curve which results from our evolutionary
simulations using simple statistical mechanics principles related to the degree of functional coupling
of the cell states. We then compare dosing strategies at early stage development, mid-stage (clinical
stage), and late stage development of the tumor. If used early during tumor development in the sub-
clinical stage, well before the cancer cell population is selected for growth, therapy is most effective
at disrupting key emergent features of tumor development.
Key words. cancer model; evolutionary game theory; Moran process; gompertzian tumor
growth; tumor heterogeneity; birth-death process
1. Introduction. At the molecular and cellular levels, cancer is an evolution-
ary process [1, 2, 3, 4] driven by random mutational events [5, 6, 7, 8] responsible
for genetic diversification which typically arises via waves of clonal and sub-clonal
expansions [9, 10], operating over an adaptive fitness landscape in which Darwinian
selection favors highly proliferative cell phenotypes which in turn drive rapid tumor
growth [11, 12, 13]. The tumor environment should be viewed as a complex Darwinian
adaptive eco-system consisting of cell types which have evolved over many years [1].
As a result, all but the most well designed and tailored therapeutic strategies often
deliver disappointing outcomes and potentially introduce a potent new source of se-
lective pressure for the proliferation of variant cells which develop an enhanced ability
to resist future therapeutic assaults [14, 15, 16, 17, 18]. The prospects for influenc-
ing and controlling such a system are likeliest at the emerging early stages of tumor
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2development when the cell population has not yet been selected for growth and sur-
vival, and the tumor size is small. But by the time a typical tumor becomes clinically
detectable (often after several years of growth), it already contains O(108) or more
malignant cells (and potentially occupies a volume of 1− 2 mm3), some of which may
have entered the blood circulation [12]. Since there is very little human data available
in this early subclinical stage of tumor development, computational models can serve
as a useful surrogate in this critical developmental stage which clearly influences and
determines many important emergent features of the tumor at later stages.
Our goals in this paper are to describe a mathematical model for stochastic
cell kinetics in the beginning stages of tumor development (from a single malignant
cell) that includes cell reproduction and death, mutations, evolution, and the sub-
sequent emergence of genetic heterogeneity well documented in many soft-tissue tu-
mors [19, 20, 21, 22, 23, 24, 25, 46, 54]. The model is a computational one, driven
by a stochastic Moran (birth-death) process with a finite cell population, in which
birth-death rates are functions of cell fitness. The fitness is determined by the cell’s
numerical genome in the form of a four-digit binary string capable of undergoing
point mutational dynamics with one digit in the string flipping values stochastically.
The corresponding numerical value of the binary string determines whether the cell
is healthy (low-fitness) or cancerous (high fitness). These two classes of cells com-
pete against each other at each birth-death event, with fitness calculated according to
the payoff matrix associated with the prisoner’s dilemma evolutionary zero-sum game
[26, 27, 28, 29]. The healthy cells play the role of cooperators, while the cancer cells
play the role of defectors [27, 29]. Our goal is to understand how the model parame-
ters: passenger (mp) and driver mutation rates (md), selection strength (w), birth and
death rates, affect tumor growth characteristics, such as tumor growth rates, fixation
probabilities of malignant and healthy cell types, saturation rates of cancer cells, and
the emergence of genetic heterogeneity in a tumor at later stages of development when
the tumor is clinically detectable.
An important outcome of the model is that growth of the cancer cell population
is directly influenced by the intratumor heterogeneity (represented as the distribution
of the 4-digit binary strings throughout the cell population), with high heterogeneity
driving more rapid growth. The connection between heterogeneity and growth has
been discussed in the literature [30, 31, 32, 33, 34, 54]. We quantify heterogeneity in
a tumor using tools from information theory [36, 37], as well as quantitative analysis
of phylogenetic trees associated with clonal and sub-clonal expansions [38, 46] in the
developing tumor. Because our numerical simulations are carried out from initial
conditions corresponding to a homogeneous population of healthy cells (0000) all the
way to a saturated population of cancer cells, we can use the model to test basic dose
and scheduling strategies [39, 40] at the very early stages of tumor development in
the subclinical range, well before a tumor would be clinically detectable by current
technology. Our point of view is that this emerging subclinical tumor should be more
amenable (and potentially vulnerable) to a well planned therapeutic assault than
a more mature tumor comprised (on average) of larger numbers of cells with more
aggressive proliferative capabilities (having undergone generations of selection), that
are potentially in the early stages of migration to other organs. More complex features
that might influence early stage dynamics, like human-immune response [32] and the
tumor microenvironment [50] are not included in this model in order to keep things
as simple and clear as possible.
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2. Description of the model. The ingredients in our model includes a stochas-
tic birth-death process that is the engine which drives tumor growth, with heritable
mutations operating over a fitness landscape so that natural selection can play out
over many cell division timescales. Genetic mutations (point mutations) are modeled
using a four-digit binary string of information that each cell carries with it.1 This
simple sequence divides the cells into 16 different “genotypes”, ranging from 0000 up
to 1111, and this information is passed on to the daughter cell during a birth event.
The birth-death replacement process is based on a fitness function defined in terms
of interactions quantified by the prisoner’s dilemma payoff matrix which operates on
two general classes of cells: healthy (the cooperators), and cancerous (the defectors).
Natural selection acts on each generation of the cell population as the computational
simulation proceeds on a cell division timescale. In this version of the model we
typically simulate up to O(1011) cell divisions, so our mutation rates are chosen to
be relatively high to accommodate these somewhat modest timescales. See [7] for
discussions on mutation rates in cancer.
2.1. The Moran birth-death process. The stochastic engine [41] that drives
tumor growth in our model is a finite cell-based Moran process consisting of a popula-
tion of N cells, divided into two sub-populations consisting of i cancer cells, and N − i
healthy cells. In all of our simulations, N is large enough so that there is not a signif-
icant difference between the results from our finite-cell model and the (deterministic)
replicator equation approach for infinite populations, a connection that is discussed in
detail in [53]. At each time-step in the simulation, one cell is chosen for reproduction
and one cell is chosen for elimination. The cells are chosen randomly, based on their
prevalence in the population pool which, in turn, is weighted by the fitness function
based on a chosen payoff matrix. The probability of choosing a cancer cell at any
given step is i/N , while the probability of choosing a healthy cell is (N − i)/N . As it
unfolds, the process is a stochastic birth-death process where the total population size,
N , stays constant and the number of cancer cells in the population, i, is the stochastic
state variable. At any given step, the probability of transitioning from i cancer cells
to j cancer cells is denoted Pij , with j = i + 1 or j = i − 1. These probabilities are
determined by the birth/death rates associated with the cancer cell population, which
in turn are determined by a cell population fitness function. Each cell carries with
it a binary string in the form of a four digit binary sequence from 0000 up to 1111.
This defines 16 different cell types, which are course-grained into two groups: healthy
cells (0000 - 1010), and cancer cells (1011-1111). These two sub-populations interact
at each birth-death time-step with fitness defined in terms of the prisoner’s dilemma
payoff matrix. The algorithmic details are shown in the appendix Figure A.1. To set
the stage for more complex simulations, Figure 2.1 shows the result of a stochastic
simulation (depicting i) driven by the Moran process alone, with no mutations, and
no selection. Figure 2.1 shows three different simulations, one leading to the elimi-
nation of all cancer cells via random drift (red), another fluctuates between a mixed
cell population after 10,000 cell divisions (yellow), and a third leading to fixation of
the cancer cell population (blue) after around 5000 cell divisions. The average of
25 stochastic simulations is also plotted (note that the average will converge to half
cancer cells and half healthy cells by the law of large numbers). The mean time to
1To be clear, the four digit sequence is not meant as a bare-bones representation of the full
human genome, but as a simple representation of the relevant differences in genetic information
contained in different cells, allowing us to course-grain the cells into 16 different categories based on
their genetic/epigenetic profiles.
4fixation of the cancer cell population which starts with ‘i’ cells in this simple setting
(no mutations, no selection) is given by
k = N
 i∑
j=1
N − i
N − j +
N−1∑
j=i+1
i
j
 .(2.1)
With no mechanism for natural selection, there is no shape to the growth curves.
Fig. 2.1: Stochastic Moran birth-death process. Cancer cell population, i(t),
during three stochastic simulations of the Moran birth-death process in a population
of 100 cells and an initial condition of i = 50 cells. The blue curve leads to fixation
of the cancer cell population, the red curve leads to elimination of the cancer cell
population, and the yellow curve remains fluctuating in a mixed population of cells
after 10,000 cell divisions. An average of 25 stochastic simulations (black dashed line)
is also plotted.
2.2. The prisoner’s dilemma payoff matrix. To introduce the effect of se-
lection which will regulate cell birth and death rates, we use the prisoner’s dilemma
evolutionary game in which two players compete against each other for the best pay-
off. Each has to decide whether to cooperate (healthy cell) or defect (cancer cell) and
each receives a payoff determined from the prisoner’s dilemma payoff matrix2, A:
A =
(
a b
c d
)
=
(
3 0
5 1
)
.(2.2)
2What defines a prisoner’s dilemma matrix are the inequalities c > a > d > b. The chosen values
in (2.2) are relatively standard, but not unique. More discussion of why the prisoner’s dilemma
matrix, which models the evolution of defection, is a useful paradigm for cancer can be found in [55]
and some of the references therin.
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The essence of the prisoner’s dilemma game is the two players compete against
each other, and each has to decide what best strategy to adopt in order to maximize
their payoff. This 2 x 2 matrix assigns the payoff (e.g. reward) to each player on each
interaction. My options, as a strategy or, equivalently, as a cell type, are listed along
the rows, with row 1 associated with my possible choice to cooperate, or equivalently
my cell type being healthy, and row 2 associated with my possible choice to defect, or
equivalently my cell type being cancerous. Your options are listed down the columns,
with column 1 associated with your choice to cooperate (or you being a healthy cell),
and column 2 associated with your choice to defect (or you being a cancer cell). The
analysis of a rational player in a prisoner’s dilemma game runs as follows. I do not
know what strategy you will choose, but suppose you choose to cooperate (column 1).
In that case, I am better off defecting (row 2) since I receive a payoff of 5 instead of 3
(if I also cooperate). Suppose instead you choose to defect (column 2). In that case, I
am also better off defecting (row 2) since I receive a payoff of 1 instead of 0 (if I were to
have cooperated). Therefore, no matter what you choose, I am better off (from a pure
payoff point of view) if I defect. What makes this game such a useful paradigm for
strategic interactions ranging from economics, political science, biology [55], and even
psychology [27] is the following additional observation. You will analyze the game
in exactly the same way I did (just switch the roles of me and you in the previous
rational analysis), so you will also decide to defect no matter what I do. The upshot
if we both defect is that we will each receive a payoff of 1, instead of each receiving
a payoff of 3 if we had both chosen to cooperate. The defect-defect combination is a
Nash equilibrium [26], and yet it is sub-optimal for both players and for the system
as a whole. Rational thought rules out the cooperate-cooperate combination which
would be better for each player (3 points each) and for both players combined (6
points). In fact, the Nash equilibrium strategy of defect-defect is the worst possible
system wide choice, yielding a total payoff of 2 points, compared to the cooperate-
defect or defect-cooperate combination, which yields a total payoff of 5 points, or the
best system-wide strategy of cooperate-cooperate yielding a total payoff of 6 points.
The game becomes even more interesting if it is played repeatedly [26, 27, 28, 29],
with each player allowed to decide what strategy to use on each interaction so as to
accumulate a higher payoff than the competition over a sequence of N games. In order
to analyze this kind of an evolving set-up, a fitness function must be introduced based
on the payoff matrix A. Let us now switch our terminology so that the relevance to
tumor cell kinetics becomes clear. In this case, we randomly select pairs of cells out of
the total population at each step, and subject them to a birth-death process, basing
our birth rates and death rates on the prisoner’s dilemma payoff matrix. Thus, in
our context, it is not the strategies that evolve, as cells cannot change type based
on strategy (only based on mutations), but the prevalence of each cell type in the
population is evolving, with the winner identified as the sub-type that first reaches
fixation in the population. As the populations evolve, the fitness of the two competing
sub-populations can be tracked, as well as the overall fitness of the combined total
population of cells.
2.3. The fitness landscape. Let us start by laying out the various probabilities
of pairs of cells interacting and clearly defining payoffs when there are i cancer cells,
and N−i healthy cells in the population. The probability that a healthy cell interacts
with another healthy cell is given by (N − i − 1)/(N − 1), whereas the probability
that a healthy cell interacts with a cancer cell is i/(N − 1). The probability that a
cancer cell interacts with a healthy cell is (N − i)/(N − 1), whereas the probability
6that a cancer cell interacts with another cancer cell is (i − 1)/(N − 1). The payoffs
associated with the healthy cells and cancer cells, obtained by weighting the payoff
matrix values with appropriate probabilities, are given by (following notation in [53]):
piH =
3(N − i− 1) + 0i
N − 1 ,(2.3)
piC =
5(N − i) + 1(i− 1)
N − 1 .(2.4)
This gives rise to the average payoff associated with the population of cells:
〈pi〉 = pi
H(N − i) + piC(i)
N
.(2.5)
Based on these formulas, we define the fitness of the healthy cells as:
fH = 1− wH + wHpiH ,(2.6)
and the fitness of the cancer cells as:
fC = 1− wC + wCpiC .(2.7)
Here, (wH , wC) are ‘selection strength’ parameters, 0 ≤ wH ≤ 1, 0 ≤ wC ≤ 1, that
measure the strength of selection pressure on each of the population of cells. If wH = 0,
there is no natural selection acting on the healthy cell population and the dynamics
is driven purely by the Moran process. When wH = 1, the selection pressure on
the healthy cell population is strongest and the prisoner’s dilemma payoff matrix has
maximum effect. Likewise for the parameter wC and how it controls selection pressure
in the cancer cell population. Since therapy imposes selection pressure on different
sub-populations of cells, wH and wC are the two parameters we alter to administer
simulated therapeutic responses. We discuss this in section §3.5.
The expected fitness of each of the sub-populations are:
φH =
N − i
N
fH ,(2.8)
φC =
i
N
fC ,(2.9)
with total expected fitness:
φ = φHi + φ
C .(2.10)
From these formulas, we can define the transition probability of going from i to i+ 1
cancer cells on a given step:
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Pi,i+1 =
ifC
ifC + (N − i)fH
N − i
N
.(2.11)
The first term represents that probability that a cancer cell is selected for reproduction
(weighted by fitness), and a healthy cell is selected for death. Likewise, the transition
probability of going from i to i− 1 cancer cells on a given step is:
Pi,i−1 =
(N − i)fH
ifC + (N − i)fH
i
N
.(2.12)
Here, the first term is the probability healthy cell is selected for reproduction (weighted
by fitness), and a cancer cell is selected for death. The remaining transition proba-
bilities are as follows:
Pi,i = 1− Pi,i+1 − Pi,i−1; P0,0 = 1; PN,N = 1.(2.13)
It is these simple formulas that drive the subsequent dynamics of the competing
populations of cells and determine the emergent features of the forming tumor (cancer
cell population). A typical set of simulations of the evolving fitness of the healthy
cell population, φH , the cancer cell population φC , and the total fitness, φ, is shown
in Figure 2.2 as the selection parameter varies from 0 to 1 (wH = wC ≡ w). As the
population evolves, the fitness of the healthy cell population decreases, the fitness of
the cancer cell population increases (sometimes reaching a maximum point), while
the total population fitness decreases.
(a) (b) (c)
Fig. 2.2: Fitness as a function of the selection parameter w ≡ wH ≡ wC . (a)
Fitness of healthy cell sub-population φH ; (b) Fitness of cancer cell sub-population
φC ; (c) Total fitness of the entire population, φ.
2.4. Passenger and driver mutations. Two remaining parameters in our
model are the passenger mutation rate, mp and the driver mutation rate, md [7].
Passenger mutations confer no fitness advantage, hence mp controls point mutations
that act on the digit strings that define the 11 levels of healthy cells 0000-1010, and
the 5 levels of cancer cells 1011-1111. A mutation diagram is shown in Figure 2.3
8depicting all of the possible point mutation transitions at each step. Mutations that
stay within either of those two ranges do not alter the cell fitness. On the other hand,
the driver mutation parameter controls mutations that take a binary string from a
healthy cell and, via a point mutation, alter it so that the string becomes a can-
cer cell3. A simple example would be a mutation that alters 1010 (healthy) to 1011
(cancer) by stochastically flipping the first digit from 0 to 1. The interested reader
can consult the flow diagram in Figure A.1 of the Appendix for more details of the
algorithm. The full code is available from the authors upon request.
Fig. 2.3: Markov Point Mutation Diagram. Left: diagram shows 16 genetic cell
types based on 4-digit binary string and the effect of a point mutation on each cell
type. Blue indicates healthy cell type (0000 — 1010), red indicates cancerous cell
type (1011 — 1111). Black arrows indicate passenger mutations (healthy to healthy
or cancer to cancer), red arrows indicate driver mutations (healthy to cancer). Top
right: 3 scenarios may occur during the reproduction process: no mutation, passenger
mutation, or driver mutation.
3. Results. Gompertzian growth arising from multicellular systems occurs in
many settings with different physical and biological constraints acting in concert.
Hence it appears as if this universal growth curve does not depend on specific physical
mechanisms (e.g. oxygen diffusion, blood supply, tumor microenvironment, etc.) but
more on multi-cellularity and the ability for populations of cells to assume a heteroge-
neous distribution of functional states, as was described most clearly in Kendal’s 1985
paper [30] and documented clinically in breast [40] and other tumor types. Alternative
bio-mechanistic models of tumor growth at the cellular level have been developed (see
[47, 48, 49, 50, 51, 52]) although do not generally include molecular information or
3In our simulations, we assume that driver mutations cannot revert to passenger mutations, i.e.
once a cancer cell is born, it stays in that category. We do not know of any evidence in the literature
that shows the reversion of a cancer cell to a healthy cell, nor is this particularly a focus of this
manuscript.
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evolutionary effects. Features of the Gompertzian growth curve defined by eqns (3.1),
(3.2) allow us to clearly describe three distinct growth regimes, the earliest being sub-
clinical and the most critical regime in which to influence future tumor kinetics, the
second being the clinical regime where growth measurements are typically obtained
[12], and the third being the lethal burden phase where growth saturates. The growth
equation, (3.9), relates tumor heterogeneity to growth rates, and we quantify hetero-
geneity via the Shannon entropy [36, 37] of the cellular population. One of the main
features of our evolutionary simulations is to show how it (i) leads to Gompertzian
growth, (ii) how growth is driven by heterogeneity quantitated via Shannon entropy,
(iii) how the initiation of heterogeneity and fitness can be tracked via dynamic phylo-
genetic trees, and (iv) how tumor kinetics can be influenced via therapeutic strategies
that target heterogeneity best in earlier growth regimes. In keeping consistent with
the notation of the Gompeterzian growth curve, we now represent the tumor growth
as the proportion of cancer cells in the population, nG(t).
3.1. Gompertzian tumor growth and three growth regimes. The basic
(top-down) equations giving rise to pure Gompertzian growth [43, 44, 45] are the
coupled equations:
dnG
dt
= γnG,(3.1)
dγ
dt
= −αγ.(3.2)
Here, is the proportion of growing cancer cells in the mixed population, which
grows exponentially according to (3.1), but with a time-dependent growth rate which
is exponentially decaying according to (3.2). It is straightforward to integrate (3.1)
to obtain:
nG(t) = N0 exp
[(
1
t
∫ t
0
γdt
)
· t
]
.(3.3)
Then, (3.2) is solved with:
γ(t) = γ0 exp(−αt).(3.4)
Plugging (3.4) into (3.3) and integrating yields the Gompertzian curve:
nG(t) = N0 exp
[γ0
α
(1− exp(−αt))
]
,(3.5)
where in the long-time limit , the population saturates to the value
n∞ = N0 exp(γ0/α),(3.6)
which we normalize to one (without loss of generality). The key features of Gom-
pertzian growth are shown in Figure 3.1. As the cancer cell proportion nG(t) in-
creases (Figure 3.1a), there are three distinct growth regimes defined by the inflection
10
point on the nG growth curve (maximum of n˙G and d
2nG/dt
2 = 0), and the two
inflection points on the growth-velocity curve n˙G (maximum/minimum of n¨G and
d3nG/dt
3 = 0). As shown in Figure 3.1(a), there are three points that divide the
growth curve into four distinct regions. For convenience, and symmetry, we lump the
second and third regions together and define three basic growth regimes:
• Regime 1 (Subclinical): Increasing velocity n˙G, increasing acceleration d2nG/dt2.
Cell population and tumor volume grows at an exponential rate;
• Regime 2 (Clinical): In this regime, n˙G reaches its maximum value. In the
early part of the regime, n˙G is increasing while d
2nG/dt
2 decreases. In the
later part of the regime, n˙G is decreasing and d
2nG/dt
2 becomes negative
(deceleration). Growth rates are clinically typically measured as linear;
• Regime 3 (Saturation/Lethal): Decreasing tumor velocity n˙G with decreas-
ing deceleration. Growth rate rapidly slows towards full saturation of the
cancer cell population.
(a) (b)
(c) (d)
Fig. 3.1: Gompertzian equation. Numerical simulation of the Gompertzian equa-
tion (3.1), (3.2) with parameters N0 = 0.001, γ0 = 10, and α = 0.2895. The three
regimes of tumor growth are demarcated by the blue dots in each subfigure, represent-
ing the maximum and minimum of the second-derivative. (a) Cancer cell proportion,
n(t), over time; (b) First- and second-derivatives of the tumor growth curve; (c)
Growth rate, γ(t), over time, with the average growth rate in regimes 1, 2, 3 plotted
in red; (d) First derivative of growth rate.
Regime 1, generally speaking, is the subclinical growth regime where the develop-
ing tumor has substantially fewer than 108 malignant cells with a tumor size smaller
than 1 or 2 mm3. Typically, the clinically measurable regime is Regime 2, while the
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lethal stage when the tumor saturates is associated with Regime 3. In reality, the
boundaries of these regimes are, of course, not sharp and depend on tumor type and
location which influence detectability. But the clarity of the pure Gompertzian curve
gives a useful framework which delineates the three distinct growth regimes based on
clear principles associated with growth, velocity, and acceleration. The growth rate
curve is shown in Figure 3.1c, with its derivatives shown in Figure 3.1d. It is most
instructive to show the average growth rates defined in each of the three regimes, also
shown in the Figure 3.1c. The average growth rate in the time interval from t1 to t2
is defined as:
γave =
1
t2 − t1
∫ t2
t1
γ(t)dt(3.7)
The subclinical regime 1 has the highest average growth, whereas regime 2, where
tumor growth is typically measured, average growth rates are lower, followed by the
lowest average growth in the clinically lethal regime 3. This implies that clinically
measured growth rates typically underestimate growth rates that preceded it in the
subclinical stage. It also implies that linear extrapolation back from clinically mea-
sured growth rates to estimate tumor initiation times (see [11, 12, 13]) will system-
atically overestimate the amount of time the tumor has been developing before being
measured. While this might generally be seen as good news (since the cancer initia-
tion event was more recent than estimated via linear extrapolation), it also gives the
clinician a shorter window of time in which to act.
3.2. Heterogeneity and growth via statistical mechanics. Kendal [30] lays
out a clear argument of how this growth curve arises from a purely statistical me-
chanics point of view. In a nutshell, his argument can be explained by considering a
population of n cells, let the jth cell (j = 1, 2, 3, . . . , n) have the potential to assume
one of qj possible states. The number of combinations of states possible within the
population, P , can be thought of as a measure of intra-neoplastic diversity:
P = q1q2q3...qn,(3.8)
and is related to the growth rate of a tumor via the equation:
dn
dt
= α logP,(3.9)
where n(t) is the number of cells capable of proliferation at a given time t and α is a
parameter that sets the timescale of growth 4. There are two basic cases to consider.
First, suppose the cells have no interaction at all, say in the earliest stages of tumor
4Kendal’s formulation [30] assumes a cell population made up of three sub-groups: (1) prolif-
erative cells; (2) nonproliferative and nonclonogentic cells; (3) nonproliferative but clonogenic cells,
with an assumption that the neoplasm’s growth rate is influenced by the proportion of proliferating
to nonproliferating cells and an expression of each clone’s growth potential. The log is chosen based
on the fact that heterogeneity is measured as the multiplicative combination of achievable states in
the tumor, and the requirement that G(P1 ·P2) = G(P1)+G(P2) for any two sub-populations P1, P2
and growth function G. The discussion of the relationship between tumor heterogeneity and growth
is an ongoing topic in the current literature [19, 20, 23, 25, 46].
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md mp tEmax tSAT nd np γave,1 γave,2 γave,3
0.4 0.1 5.50e+5 1.830e+6 1.289e+4 4.68e+4 3.14e-5 3.68e-6 1.448e-7
0.3 0.2 4.88e+5 1.753e+6 1.682e+4 8.26e+4 4.04e-5 4.31e-6 1.677e-7
0.2 0.3 4.85e+5 1.761e+6 1.715e+4 1.230e+4 3.86e-5 4.41e-6 1.729e-7
0.1 0.4 5.40e+5 1.426e+6 1.362e+4 1.836e+4 3.04e-5 3.81e-6 1.658e-7
Table 3.1: md: driver mutation rate; mp : passenger mutation rate; tEmax: time
to maximum entropy; tSAT : time to saturation; nd: number of driver mutations;
np: number of passenger mutations; γave,1: average growth rate in regime 1; γave,2:
average growth rate in regime 2; γave,3: average growth rate in regime 3.
development, and let each of the n cells have the ability to assume one of m possible
states. Then, P = mn, and the growth equation becomes
dn
dt
= αn logm = (α logm)n.(3.10)
The solution to this equation is the exponentially growing population:
n(t) = N0 exp((α logm)t).(3.11)
Thus, early stage development is characterized by exponential growth (regime 1),
with a growth rate proportional to the log of the number of assumable states of the
cells comprising the tumor population. This stage is characterized by the Gompertzian
curve shown in Figure 3.1a to the left of the first blue dot, in regime 1. Contrast this
with later stages of tumor growth, when the sub-populations of cells communicate and
influence each other’s growth characteristics, either via competition, or cooperation
(regime 3) within the tumor microenvironment. In effect, this will constrain (reduce)
the number of assumable states of each cell, since the population is effectively coupled.
In the extreme, suppose P = mn/nn. In other words, suppose P is now inversely
related to the total number of possible intercellular interactions. Inserting this into
(3.9) yields
dn
dt
= α log
(
(
m
n
)n
)
= αn [logm− log n] .(3.12)
The solution to this equation is exactly the Gompertzian growth curve (3.5)
and accounts for regimes 2 and 3 previously discussed in which tumor growth slows
down. The growth equation (3.9) which relates cancer cell population growth to
tumor heterogeneity is capable of producing a family of growth curves, depending
on details of intercellular coupling, which of course is influenced by details of the
biological and physical constraints influencing the tumor microenvironment. Thus,
the growth equation (3.9) has the ability to produce different detailed shapes based
on assumptions associated with intercellular coupling. Table 3.1 shows the average
growth rates in the three regimes as a function of the key parameters in the model.
3.3. Quantitative measures of tumor heterogeneity and growth. For
our purposes, we measure heterogeneity using the Shannon entropy from information
theory [36]:
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E(t) = −
N∑
i=1
pi log2 pi,(3.13)
(here, log is defined as base 2). The probability pi measures the proportion of cells
of type i, with i = 1, ..., 16 representing the distribution of binary strings ranging
from 0000 to 1111. We then course-grain this distribution further so that cells having
strings ranging from 0000 up to 1010 are called “healthy”, while those ranging from
1011 to 1111 are “cancerous”5. The growth equation (3.9) then becomes
dnE
dt
= αE(t).(3.14)
It follows from (3.14) that the cancer cell proportion nE(t) can be written in
terms of entropy as:
nE(t) = α
∫ t
0
E(t)dt.(3.15)
The panel in Figure 3.2 shows the results from our cell-based simulations. Figure 3.2a
shows the Gompertzian curve associated with the proportion of cancer cells in the pop-
ulation, while Figure 3.2b shows the velocity and accelerations associated with growth,
and can be compared with Figure 3.1b. In Figure 3.2c we show the entropy during a
typical simulation, marking the maximum entropy point which peaks relatively early
in the simulation before the entropy returns back down to zero, reflecting the fact
that cancer cells have reached fixation and have saturated the population. Figure
3.2d shows the fitness of the cancer cell sub-population, healthy cell sub-population,
and the overall tumor fitness (wH = wC ≡ w = 0.5). As a typical simulation pro-
ceeds, the cancer cell sub-population fitness increases, the healthy cell sub-population
fitness decreases, while the overall tumor fitness decreases. Figure 3.2e, 3.2f shows the
Gompertzian growth curves as the selection pressure increases (Figure 3.2e) and as
the mutation rate increases (Figure 3.2f). High values for either of these parameters
leads to a very steep growth curve, as is expected.
Figure 3.3 shows the growth curves linearly extrapolated back to give a prediction
of when the first driver mutation occurred that initiated tumor growth. The growth
rates from regime 2 (linear regime) are used to extrapolate back to the initiation
event. Since the actual growth rate in regime 1 is much faster than linear, the linear
extrapolation extends the event too far back in time as compared to when the event
actually occurred. The inset of Figure 3.3 shows histograms of the average growth
rates in each of the three regimes as a function of the mutation rate m (here, we take
mp = md = m).
A typical stochastic simulation showing the evolution of all 16 possible cell types
is shown in Figure 3.4. We also show E(t), where entropy is computed using the
most extreme course-grained two-state system comprised of the two sub-populations
of healthy cells and cancer cells. We compare in Figure 3.4 the Gompertzian growth
curve (eqn. (3.5)) and the corresponding curve obtained from eqn. (3.15) to the
5Our results are relatively insensitive to where we draw the dividing line between healthy and
cancerous.
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(a) (b)
(c) (d)
(e) (f)
Fig. 3.2: Moran birth-death process with selection. (a) Cancer cell population,
i(t) (w = 0.5, m = 0.2, N = 1010) plotted with a spline curve connecting 200
data points from a single stochastic simulation; (b) First- and second-derivatives of
the tumor growth curve in (a) are plotted with maximum and minimum of second-
derivative indicated (blue); (c) Entropy of the cell population from eqn. (3.13) as
it relates to the growth equation (3.14); (d) Fitness of healthy cell population and
cancer cell population and total fitness as defined by eqns. (2.8), (2.9), (2.10); (e)
Simulations of cancer cell population, i(t), for a range of selection parameter values;
(f) Simulations of cancer cell population, i(t), for a range of mutation rate values.
stochastic simulation and the agreement is excellent. Likewise, we also show a com-
parison of dn/dt with eqn. (3.14) and eqn. (3.1) with E(t) normalized so that limiting
values match the stochastic simulation, and the agreement is also excellent. In the
beginning, entropy is zero, since the population consists purely of healthy cells, and
in the end of the simulation, entropy is again zero as the population consists purely of
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Fig. 3.3: Tumor initiation prediction. Five sample stochastic simulations of tumor
growth (N = 1010 cells, w = 0.5, m = 0.1, 0.2, 0.3, 0.4, 0.5) plotted on a log-linear
graph where the model output (i(t), solid lines) is fit in the clinical regime (greater
than 108 cells) using an exponential growth equation and extrapolated backwards in
simulation time (dashed lines). The inset bar graph shows the average growth rate in
each regime.
cancer cells. Entropy peaks somewhere early in the simulation when the mixture of
cell types is equally distributed over cancer and healthy types. It is this intermediate
but important heterogeneously distributed state that is the key driver of growth, as
is clear from eqn. (3.14).
3.4. Dynamic phylogenetic trees and evolution of fitness. To track the
initiation of cellular heterogeneity from an initially homogeneous state, we follow all
of the mutations that take place during the course of a simulation, and organize
this in the form of a phylogenetic tree in Figure 3.5 showing the typical size of the
genotypic space and the evolution of the genotypic landscape. As the simulation
proceeds, the phylogenetic tree dynamically branches out into an increasingly complex
structure, with fitness characteristics color coded in Figure 3.5a. We also show the
bins associated with each of the 16 cell types, the number of cancer cells i(t), and the
entropy associated with the sub-population of cell types as a simulation proceeds, in
Figure 3.5b. Knowing exactly the types of cells comprising the tumor at any given
time allows us to target cell distributions for simulated therapies to test different
strategies, which we describe next.
3.5. A comparison of early vs. late therapy. In Figure 4.1 we show the
results from asking the simple question of how early therapy (administered in regime
1) compares with therapy in the middle stages of tumor development (regime 2), or
in the later stages of development (regime 3). Eqns (2.11), (2.12) are the governing
equations controlling birth/death rates of the cancer cell, healthy cell sub-populations
as natural selection plays out. Since the proliferation of cancer cells can be thought
of as an imbalance of selection pressures on the competing sub-populations in favor
of the cancer sub-population, the goal of any therapeutic intervention is to alter this
complex imbalance in favor of the healthy cell sub-population. We implement this by
adjusting the selection pressure parameters (wH , wC) in the formulas (2.6), (2.7). In
particular, when therapy is ‘on’, we choose wC = 0, and wH = 1, tilting the selection
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(a)
(b)
(c)
Fig. 3.4: Comparison of stochastic Moran birth-death process, Gom-
pertzian, and Shannon entropy growth curves. (a) A single stochastic sim-
ulation (N = 1010 cells, m = 0.5, w = 0.5, mp = md = 0.25) growth curve, n(t),
compared with the Gompertzian growth curve, nG(t), eqn. (3.5), and Shannon en-
tropy growth curve, nE(t), eqn. (3.15). Growth curves nG(t) and nE(t) are normalized
to equal one in the limit; (b) Comparison of first-derivatives of n(t), nE(t), nG(t); (c)
Comparison of growth rates associated with n(t), nE(t), nG(t), with average growth
rates of n(t) plotted for each regime, eqn. (3.7).
pressure in favor of the healthy cell sub-population. When therapy is ‘off’, the two
parameters return to their original baseline values, which here we take as wH = 0.1,
wC = 0.1. Figure 4.1 depicts the proportion of cancer cells in the population both
in the absence of therapy, and when therapy is administered. As a comparative tool,
in each case, we administer the therapy until a fixed number of cancer cells remains
(in each case, we take this threshold number to be 25 cancer cells), and we compare
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(a)
(b)
Fig. 3.5: Emergence of genetic heterogeneity. (a) Left: sample dendritic phylo-
genetic tree tracking point mutations as time extends radially. Right: three snapshots
in time of a dendritic tree in a simulation of 30 cells with strong selection (w = 1,
mp = 0.1, md = 0.2). Pathways are color coded to indicate genetic cell type; (b)
Linear phylogenetic tree of the same stochastic simulation shown in (a) along with
histogram plots of the distribution of genetic cell types and a plot of the cancer cell
population i(t) and entropy.
the amount of time, ∆t, it takes to achieve this low level. The figure clearly shows
∆t1 < ∆t2 < ∆t3 < ∆t4, while if therapy is administered too late, as in ∆t5, the low
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threshold is never achieved. The simulations show that a shorter therapeutic time-
period is needed if administered earlier to gain the same level of success. The topic of
how best to optimize computational therapies is complex, and these simulations are
only meant as a confirmation and quantification of how early stage therapy is more
effective than late stage therapy.
4. Discussion. To summarize the main points forming the framework of our
model:
(i) A tumor is a complex Darwinian ecosystem of competing cells operating on an
adaptive fitness landscape driven by mutational dynamics and shaped by evolutionary
pressures;
(ii) The basic competitors in an evolutionary game theory model of tumor develop-
ment are cell populations with a broad distribution of fitness characteristics course
grained into two types: healthy cells (cooperators) and cancer cells (defectors). Each
of these cell sub-populations attempts to maximize its own fitness;
(iii) Cell fitness is associated with reproductive prowess and in this respect, healthy
cells are less fit than cancer cells;
(iv) Primary tumors initiate from a single malignant cell that has undergone the
appropriate mutational steps and subsequently undergoes clonal and sub-clonal ex-
pansion. Polyclonality and heterogeneity are thus seen as emergent features of tumor
development;
(v) Parameters and distributions measured in the detectable range of tumor growth,
such as tumor growth rates and fixation probabilities, are emergent features that have
developed from a monoclonal state via cell kinetics and evolutionary development
taking place in the subclinical regime;
(vi) Tumor growth is driven by molecular heterogeneity of the cell population com-
prising the tumor and reflected in the growth equation (3.9);
(vii) Tumor cell populations are more amenable to therapeutic strategies in the early
stages of development, before selection for growth and survival have shaped the envi-
ronment.
We believe the simple evolutionary model described in this paper, driven by a
Moran process and shaped by heritable mutations with a fitness landscape based on
the prisoner’s dilemma evolutionary game is useful in helping to understand early
stage tumor growth and how it is influenced by the interplay of a few select small
number of key parameters. When a malignant tumor cell population has already
exceeded O(108 − 1010) cells, some of which may have entered the circulation or
lymphatics and migrated to other sites, the opportunity to control or even shape
future events may be limited. Attacking tumor heterogeneity as soon as it develops
seems to be a useful strategy, particularly if heterogeneity is the driver of growth, as
in eqn. (3.9). Whether these concepts can be developed in the more general context
when cell dissemination to other sites is included in the model, and then translated
into actionable clinical strategies is a challenge for the future.
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Fig. 4.1: Simulated therapy. An average of 25 stochastic simulations (N = 103
cells, w = 0.5, m = 0.1) where therapy (wH = 1, wC = 0) is administered at different
time points (t = 6000, 8000, 10000, 12000, 14000 cell divisions) until all cancer cells
are eliminated below a small threshold value (25 cells). Time required (∆t) for tumor
elimination increases as the tumor volume increases (i.e. ∆t1 < ∆t2 < ∆t3 < ∆t4,
blue, red, yellow, purple arrows respectively), until, at later simulation time points,
therapy is unable to regress tumor size (∆t5, green arrow).
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Appendix A.
Fig. A.1: A flow chart of the Moran process with selection and mutation algorithm.
Box 1: mutation rate m (where m = mp + md), selection pressure w and the initial
state vector x containing N total cells are the inputs for a simulation. Box 2: the
prisoner’s dilemma game (a = 3; b = 0; c = 5; d = 1) is used to calculate the fitness
of each healthy and cancer cell type, which is a function of the payoff values and the
state vector, x. Box 3, 4: a single cell is chosen for death according to the relative
proportion of the cell type in the cell population. Simultaneously, a single cell is
selected for birth according to the relative proportion, weighted by cell fitness. Box
5: During the replication process, the daughter cell inherits a replica of the parent
cell’s genetic string, with errors occurring at a rate of m. A single bit of the daughter
cell’s genetic string may flip during each cell division. The possible mutations can be
thought of as a single step random walk on the Markov diagram shown in Figure 2.3.
